Heterogeneous catalytic wet peroxide oxidation systems for the treatment of an industrial pharmaceutical wastewater

WATER RESEARCH

卷:43

Article

Melero, J. A.¹  Martinez, F.¹  Botas, J. A.¹  Molina, R.¹  Pariente, M. I.¹ 

[1] Rey Juan Carlos Univ, Dept Chem & Environm Technol ESCET, Madrid 28933, Spain

关键词: Advanced oxidation processes;    Catalytic wet peroxide oxidation;    Fixed bed reactor;    Iron oxide catalyst;    SBA-15;    Pharmaceutical wastewater;   

DOI  :  10.1016/j.watres.2009.04.012

来源: Elsevier

【 摘 要 】

The aim of this work was to assess the treatment of wastewater coming from a pharmaceutical plant through a continuous heterogeneous catalytic wet peroxide oxidation (CWPO) process using an Fe2O3/SBA-15 nanocomposite catalyst. This catalyst was preliminary tested in a batch stirred tank reactor (STR), to elucidate the influence of significant parameters on the oxidation system, such as temperature, initial oxidant concentration and initial pH of the reaction medium. In that case, a temperature of 80,C using an initial oxidant concentration corresponding to twice the theoretical stoichiometric amount for complete carbon depletion and initial pH of ca. 3 allow TOC degradation of around 50% after 200 min of contact time. Thereafter, the powder catalyst was extruded with bentonite to prepare pellets that could be used in a fixed bed reactor (FBR). Results in the up-flow FBR indicate that the catalyst shows high activity in terms of TOC mineralization (ca. 60% under steady-state conditions), with an excellent use of the oxidant and high stability of the supported iron species. The activity of the catalyst is kept constant, at least, for 55 h of reaction. Furthermore, the BOD5/COD ratio is increased from 0.20 to 0.30, whereas the average oxidation stage (AOS) changed from 0.70 to 2.35. These two parameters show a high oxidation degree of organic compounds in the outlet effluent, which enhances its biodegradability, and favours the possibility of a subsequent coupling with a conventional biological treatment. (C) 2009 Elsevier Ltd. All rights reserved.

【 授权许可】

Free